New Two-Pronged attack tested for Tough-to-Treat leukemia
NCT ID NCT07301424
Summary
This study is testing a combination of two drugs, blinatumomab (given as an injection under the skin) and ponatinib (a pill), for adults newly diagnosed with a specific, aggressive form of blood cancer called BCR-ABL positive acute lymphoblastic leukemia (ALL). The goal is to see how well this combination works to control the cancer and what side effects it causes. Participants will take ponatinib pills for about 5 years as part of their long-term treatment plan.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PHILADELPHIA CHROMOSOME-POSITIVE (PH+) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alberta
Edmonton, Alberta, T6G 2G3, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.